|
US5858988A
(en)
|
1993-02-24 |
1999-01-12 |
Wang; Jui H. |
Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use
|
|
US6291438B1
(en)
|
1993-02-24 |
2001-09-18 |
Jui H. Wang |
Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use
|
|
US9637739B2
(en)
|
2012-03-20 |
2017-05-02 |
Vilnius University |
RNA-directed DNA cleavage by the Cas9-crRNA complex
|
|
DK3363902T3
(da)
|
2012-12-06 |
2020-01-02 |
Sigma Aldrich Co Llc |
Crispr-baseret genommodifikation og -regulering
|
|
CN105209621B
(zh)
|
2012-12-12 |
2021-05-25 |
布罗德研究所有限公司 |
对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
|
|
PT2931898E
(pt)
|
2012-12-12 |
2016-06-16 |
Harvard College |
Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais
|
|
US9234213B2
(en)
|
2013-03-15 |
2016-01-12 |
System Biosciences, Llc |
Compositions and methods directed to CRISPR/Cas genomic engineering systems
|
|
US10584358B2
(en)
|
2013-10-30 |
2020-03-10 |
North Carolina State University |
Compositions and methods related to a type-II CRISPR-Cas system in Lactobacillus buchneri
|
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
|
SG11201608701QA
(en)
|
2014-04-18 |
2016-11-29 |
Editas Medicine Inc |
Crispr-cas-related methods, compositions and components for cancer immunotherapy
|
|
WO2016073990A2
(en)
|
2014-11-07 |
2016-05-12 |
Editas Medicine, Inc. |
Methods for improving crispr/cas-mediated genome-editing
|
|
AU2016226077B2
(en)
|
2015-03-03 |
2021-12-23 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases with altered PAM specificity
|
|
BR112017020750A2
(en)
*
|
2015-03-27 |
2018-06-26 |
President And Fellows Of Harvard College |
modified t-cells and methods of producing and using them
|
|
EP3294342A4
(en)
|
2015-05-08 |
2018-11-07 |
President and Fellows of Harvard College |
Universal donor stem cells and related methods
|
|
MX2017014560A
(es)
|
2015-05-15 |
2018-03-01 |
Pioneer Hi Bred Int |
Caracterizacion rapida de sistemas de endonucleasa cas, secuencias pam y elementos arn de guia.
|
|
US10392607B2
(en)
|
2015-06-03 |
2019-08-27 |
The Regents Of The University Of California |
Cas9 variants and methods of use thereof
|
|
US20160362667A1
(en)
|
2015-06-10 |
2016-12-15 |
Caribou Biosciences, Inc. |
CRISPR-Cas Compositions and Methods
|
|
WO2016205759A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
|
EP3929287A3
(en)
|
2015-06-18 |
2022-04-13 |
The Broad Institute, Inc. |
Crispr enzyme mutations reducing off-target effects
|
|
WO2017093969A1
(en)
*
|
2015-12-04 |
2017-06-08 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
EP3390632B1
(en)
|
2015-12-18 |
2025-09-10 |
Danisco US Inc. |
Methods and compositions for polymerase ii (pol-ii) based guide rna expression
|
|
MX2018010484A
(es)
|
2016-03-04 |
2019-01-10 |
Editas Medicine Inc |
Métodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cáncer.
|
|
EP3426780A1
(en)
|
2016-03-11 |
2019-01-16 |
Pioneer Hi-Bred International, Inc. |
Novel cas9 systems and methods of use
|
|
EP3452499A2
(en)
|
2016-05-06 |
2019-03-13 |
Juno Therapeutics, Inc. |
Genetically engineered cells and methods of making the same
|
|
WO2018035250A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute, Inc. |
Methods for identifying class 2 crispr-cas systems
|
|
WO2018041120A1
(en)
|
2016-08-31 |
2018-03-08 |
Beijing Biocytogen Co., Ltd |
Genetically modified non-human animal with human or chimeric tigit
|
|
KR20190049887A
(ko)
*
|
2016-09-29 |
2019-05-09 |
난트케이웨스트, 인크. |
감소된 면역원성을 갖는 hla 클래스 i-결핍 nk-92 세포
|
|
CA3038982A1
(en)
|
2016-09-30 |
2018-04-05 |
The Regents Of The University Of California |
Rna-guided nucleic acid modifying enzymes and methods of use thereof
|
|
WO2018074979A1
(en)
|
2016-10-17 |
2018-04-26 |
Nanyang Technological University |
Truncated crispr-cas proteins for dna targeting
|
|
WO2018073393A2
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
|
|
WO2018209712A1
(en)
|
2017-05-19 |
2018-11-22 |
Tsinghua University |
Engineering of a minimal sacas9 crispr/cas system for gene editing and transcriptional regulation optimized by enhanced guide rna
|
|
CN110168078B
(zh)
|
2017-01-06 |
2024-05-14 |
免疫生物公司 |
具有降低的cd96/tigit表达的遗传修饰的nk-92细胞
|
|
MX2019011215A
(es)
|
2017-03-24 |
2020-02-12 |
Curevac Ag |
Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos.
|
|
CN110892069B
(zh)
|
2017-03-30 |
2024-02-09 |
国立大学法人京都大学 |
基于基因组编辑的外显子跳跃诱导方法
|
|
BR112019023608A2
(pt)
|
2017-05-12 |
2020-05-26 |
Crispr Therapeutics Ag |
Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
|
|
CN107164377A
(zh)
|
2017-06-12 |
2017-09-15 |
王小平 |
基于碱基编辑的基因敲除方法及其应用
|
|
US9982279B1
(en)
|
2017-06-23 |
2018-05-29 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
|
US10011849B1
(en)
|
2017-06-23 |
2018-07-03 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
|
CN107723275B
(zh)
*
|
2017-10-20 |
2020-09-04 |
重庆精准生物技术有限公司 |
通用型car-t细胞及其制备方法和应用
|
|
BR112020009268A2
(pt)
|
2017-11-10 |
2020-11-17 |
University Of Massachusetts |
plataformas de distribuição de crispr direcionadas
|
|
US10253365B1
(en)
|
2017-11-22 |
2019-04-09 |
The Regents Of The University Of California |
Type V CRISPR/Cas effector proteins for cleaving ssDNAs and detecting target DNAs
|
|
AU2018383712B2
(en)
|
2017-12-11 |
2025-09-04 |
Editas Medicine, Inc. |
Cpf1-related methods and compositions for gene editing
|
|
WO2019161290A1
(en)
|
2018-02-15 |
2019-08-22 |
Sigma-Aldrich Co. Llc |
Engineered cas9 systems for eukaryotic genome modification
|
|
KR20200124702A
(ko)
|
2018-02-23 |
2020-11-03 |
파이어니어 하이 부렛드 인터내쇼날 인코포레이팃드 |
신규한 cas9 오르소로그
|
|
CA3093919A1
(en)
|
2018-03-15 |
2019-09-19 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
|
CN112585276A
(zh)
|
2018-04-05 |
2021-03-30 |
朱诺治疗学股份有限公司 |
产生表达重组受体的细胞的方法和相关组合物
|
|
EP3775213A1
(en)
|
2018-04-13 |
2021-02-17 |
Sigma Aldrich Co. LLC |
Modification of immune-related genomic loci using paired crispr nickase ribonucleoproteins
|
|
WO2020041120A1
(en)
|
2018-08-20 |
2020-02-27 |
Massachusetts Institute Of Technology |
Robotic manipulation of objects using external contacts
|
|
WO2020055941A1
(en)
|
2018-09-13 |
2020-03-19 |
Excision Biotherapeutics, Inc. |
Compositions and methods for excision with single grna
|
|
CN110904045A
(zh)
|
2018-09-17 |
2020-03-24 |
中国科学院动物研究所 |
经修饰的t细胞、其制备方法及用途
|
|
CA3116132A1
(en)
|
2018-10-16 |
2020-04-23 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunotherapy
|
|
UY38427A
(es)
*
|
2018-10-26 |
2020-05-29 |
Novartis Ag |
Métodos y composiciones para terapia con células oculares
|
|
KR20210116526A
(ko)
|
2019-01-16 |
2021-09-27 |
빔 테라퓨틱스, 인크. |
증진된 항-신생물 활성 및 면역억제 내성을 갖는 변형된 면역 세포
|
|
US12600971B2
(en)
|
2019-02-13 |
2026-04-14 |
Beam Therapeutics Inc. |
Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
|
|
US20220220460A1
(en)
|
2019-02-14 |
2022-07-14 |
Metagenomi Ip Technologies, Llc |
Enzymes with ruvc domains
|
|
CN113728097A
(zh)
|
2019-02-14 |
2021-11-30 |
宏基因组学知识产权技术有限责任公司 |
具有ruvc结构域的酶
|
|
US10913941B2
(en)
|
2019-02-14 |
2021-02-09 |
Metagenomi Ip Technologies, Llc |
Enzymes with RuvC domains
|
|
KR20240007322A
(ko)
|
2019-02-14 |
2024-01-16 |
메타지노미, 인크. |
Ruvc 도메인이 존재하는 효소
|
|
BR112021016046A2
(pt)
*
|
2019-02-15 |
2021-11-09 |
Editas Medicine Inc |
Células assassinas naturais modificadas (nk) para imunoterapia
|
|
JP2020154564A
(ja)
|
2019-03-19 |
2020-09-24 |
富士通株式会社 |
学習方法、学習プログラムおよび学習装置
|
|
US20220235340A1
(en)
|
2019-05-20 |
2022-07-28 |
The Broad Institute, Inc. |
Novel crispr-cas systems and uses thereof
|
|
US20220403357A1
(en)
|
2019-11-12 |
2022-12-22 |
The Broad Institute, Inc. |
Small type ii cas proteins and methods of use thereof
|
|
CA3177051A1
(en)
|
2020-03-31 |
2021-10-07 |
Metagenomi, Inc. |
Class ii, type ii crispr systems
|
|
WO2021202559A1
(en)
|
2020-03-31 |
2021-10-07 |
Metagenomi Ip Technologies, Llc |
Class ii, type ii crispr systems
|
|
CN116096892A
(zh)
|
2020-05-08 |
2023-05-09 |
宏基因组学公司 |
具有RuvC结构域的酶
|
|
WO2021226369A1
(en)
|
2020-05-08 |
2021-11-11 |
Metagenomi Ip Technologies, Llc |
Enzymes with ruvc domains
|
|
CA3192224A1
(en)
|
2020-09-11 |
2022-03-17 |
Jyun-Liang LIN |
Base editing enzymes
|
|
CN112126661B
(zh)
|
2020-09-30 |
2022-07-22 |
上海中医药大学 |
一种高效敲除nk细胞中tigit基因的方法
|
|
EP4203993A4
(en)
|
2020-10-23 |
2024-10-23 |
The Broad Institute, Inc. |
Reprogrammable iscb nucleases and uses thereof
|
|
EP4259160A4
(en)
*
|
2020-12-14 |
2025-05-14 |
Emendobio Inc. |
BIALLELIC INACTIVATION OF B2M
|
|
KR20230134543A
(ko)
*
|
2021-01-22 |
2023-09-21 |
메타지노미, 인크. |
신규한 조작된 뉴클레아제 및 키메라 뉴클레아제
|
|
JP7877351B2
(ja)
|
2021-03-19 |
2026-06-22 |
メタゲノミ セラピューティクス，インク． |
Ｃａｓ酵素を用いたマルチプレックス編集
|
|
EP4330386A4
(en)
|
2021-04-30 |
2025-05-14 |
Metagenomi, Inc. |
Enzymes with ruvc domains
|
|
CN119452085A
(zh)
|
2021-08-27 |
2025-02-14 |
宏基因组学公司 |
具有ruvc结构域的酶
|
|
KR20240110603A
(ko)
|
2021-11-24 |
2024-07-15 |
메타지노미, 인크. |
엔도뉴클레아제 시스템
|
|
WO2023097262A1
(en)
|
2021-11-24 |
2023-06-01 |
Metagenomi, Inc. |
Endonuclease systems
|
|
CA3254301A1
(en)
*
|
2022-03-14 |
2023-09-21 |
Metagenomi Therapeutics, Inc. |
MODIFIED AND CHIMERIC NUCLEASE
|